Compare FNWB & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | MAIA |
|---|---|---|
| Founded | 1923 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0M | 86.2M |
| IPO Year | 2012 | 2022 |
| Metric | FNWB | MAIA |
|---|---|---|
| Price | $10.19 | $1.27 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | 63.8K | ★ 758.6K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.68% | N/A |
| EPS Growth | ★ 36.00 | 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $176,000.00 | N/A |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.05 | $0.87 |
| 52 Week High | $10.98 | $3.19 |
| Indicator | FNWB | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 41.68 |
| Support Level | $9.26 | $1.26 |
| Resistance Level | $10.33 | $1.50 |
| Average True Range (ATR) | 0.33 | 0.10 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 84.96 | 34.69 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.